Clinical Trial Update: A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma. [Phase 2]

View source ↗

Summary

Phase II trial investigating two Sunitinib dosing schedules as first-line therapy for metastatic renal cell carcinoma; status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: UNKNOWN